Glutamine Imaging: A New Avenue for Glioma Management

References

1. 1.↵
   1. Reni M,
   2. Mazza E,
   3. Zanon S, et al

   . Central nervous system gliomas. Crit Rev Oncol Hematol 2017;113:213–34 doi:10.1016/j.critrevonc.2017.03.021 pmid:28427510

   CrossRefPubMed
2. 2.↵
   1. Pavlova NN,
   2. Thompson CB

   . The emerging hallmarks of cancer metabolism. Cell Metab 2016;23:27–47 doi:10.1016/j.cmet.2015.12.006 pmid:26771115

   CrossRefPubMed
3. 3.↵
   1. Hensley CT,
   2. Wasti AT,
   3. DeBerardinis RJ

   . Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest 2013;123:3678–84 doi:10.1172/JCI69600 pmid:23999442

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Márquez J,
   2. Alonso FJ,
   3. Matés JM, et al

   . Glutamine addiction in gliomas. Neurochem Res 2017;42:1735–46 doi:10.1007/s11064-017-2212-1 pmid:28281102

   CrossRefPubMed
5. 5.↵
   1. Vander Heiden MG,
   2. DeBerardinis RJ

   . Understanding the intersections between metabolism and cancer biology. Cell 2017;168:657–69 doi:10.1016/j.cell.2016.12.039 pmid:28187287

   CrossRefPubMed
6. 6.↵
   1. Hu S,
   2. Balakrishnan A,
   3. Bok RA, et al

   . 13C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression. Cell Metab 2011;14:131–42 doi:10.1016/j.cmet.2011.04.012 pmid:21723511

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Nicklin P,
   2. Bergman P,
   3. Zhang B, et al

   . Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 2009;136:521–34 doi:10.1016/j.cell.2008.11.044 pmid:19203585

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Le A

   1. Li T,
   2. Copeland C,
   3. Le A

   . Glutamine metabolism in cancer. In: Le A, ed. The Heterogeneity of Cancer Metabolism. Springer-Verlag International Publishing; 2021:17–38
9. 9.↵
   1. Cluntun AA,
   2. Lukey MJ,
   3. Cerione RA, et al

   . Glutamine metabolism in cancer: understanding the heterogeneity. Trends Cancer 2017;3:169–80 doi:10.1016/j.trecan.2017.01.005 pmid:28393116

   CrossRefPubMed
10. 10.↵
    1. Oizel K,
    2. Chauvin C,
    3. Oliver L, et al

    . Efficient mitochondrial glutamine targeting prevails over glioblastoma metabolic plasticity. Clin Cancer Res 2017;23:6292–6304 doi:10.1158/1078-0432.CCR-16-3102 pmid:28720668

    Abstract/FREE Full Text
11. 11.↵
    1. Koch K,
    2. Hartmann R,
    3. Tsiampali J, et al

    . A comparative pharmaco-metabolomic study of glutaminase inhibitors in glioma stem-like cells confirms biological effectiveness but reveals differences in target-specificity. Cell Death Discov 2020;6:20 doi:10.1038/s41420-020-0258-3 pmid:32337072

    CrossRefPubMed
12. 12.↵
    1. Oizel K,
    2. Yang C,
    3. Renoult O, et al

    . Glutamine uptake and utilization of human mesenchymal glioblastoma in orthotopic mouse model. Cancer Metab 2020;8:9 doi:10.1186/s40170-020-00215-8 pmid:32789014

    CrossRefPubMed
13. 13.↵
    1. Venneti S,
    2. Dunphy MP,
    3. Zhang H, et al

    . Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Sci Transl Med 2015;7:274ra17 doi:10.1126/scitranslmed.aaa1009 pmid:25673762

    Abstract/FREE Full Text
14. 14.↵
    1. Subramani E,
    2. Radoul M,
    3. Najac C, et al

    . Glutamate is a noninvasive metabolic biomarker of IDH1-mutant glioma response to temozolomide treatment. Cancer Res 2020;80:5098–5108 doi:10.1158/0008-5472.CAN-20-1314 pmid:32958546

    Abstract/FREE Full Text
15. 15.↵
    1. Byun JK,
    2. Park M,
    3. Lee S, et al

    . Inhibition of glutamine utilization synergizes with immune checkpoint inhibitor to promote antitumor immunity. Mol Cell 2020;80:592–606.e8 doi:10.1016/j.molcel.2020.10.015 pmid:33159855

    CrossRefPubMed
16. 16.↵
    1. Choi YK,
    2. Park KG

    . Targeting glutamine metabolism for cancer treatment. Biomol Ther (Seoul) 2018;26:19–28 doi:10.4062/biomolther.2017.178 pmid:29212303

    CrossRefPubMed
17. 17.↵
    1. Altman BJ,
    2. Stine ZE,
    3. Dang CV

    . From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer 2016;16:619–34 doi:10.1038/nrc.2016.71 pmid:27492215

    CrossRefPubMed
18. 18.↵
    1. Kizilbash SH,
    2. McBrayer S,
    3. Port J, et al

    . A phase Ib trial of CB-839 (telaglenastat) in combination with radiation therapy and temozolomide in patients with IDH-mutated diffuse astrocytoma and anaplastic astrocytoma (NCT03528642). J Clin Oncol 2019;37:TPS2075 doi:10.1200/JCO.2019.37.15_suppl.TPS2075

    CrossRef
19. 19.↵
    1. Lenting K,
    2. Verhaak R,
    3. Ter Laan M, et al

    . Glioma: experimental models and reality. Acta Neuropathol 2017;133:263–82 doi:10.1007/s00401-017-1671-4 pmid:28074274

    CrossRefPubMed
20. 20.↵
    1. Öz G,
    2. Alger JR,
    3. Barker PB, et al

    ; MRS Consensus Group. Clinical proton MRS in central nervous system disorders. Radiology 2014;270:658–79 doi:10.1148/radiol.13130531 pmid:24568703

    CrossRefPubMed
21. 21.↵
    1. Ekici S,
    2. Risk BB,
    3. Neill SG, et al

    . Characterization of dysregulated glutamine metabolism in human glioma tissue with 1H NMR. Sci Rep 2020;10:20435 doi:10.1038/s41598-020-76982-7 pmid:33235296

    CrossRefPubMed
22. 22.↵
    1. Hingerl L,
    2. Strasser B,
    3. Moser P, et al

    . Clinical high-resolution 3D-MR spectroscopic imaging of the human brain at 7 T. Invest Radiol 2020;55:239–48 doi:10.1097/RLI.0000000000000626 pmid:31855587

    CrossRefPubMed
23. 23.↵
    1. Ganji SK,
    2. An Z,
    3. Tiwari V, et al

    . In vivo detection of 2-hydroxyglutarate in brain tumors by optimized point-resolved spectroscopy (PRESS) at 7T. Magn Reson Med 2017;77:936–44 doi:10.1002/mrm.26190 pmid:26991680

    CrossRefPubMed
24. 24.↵
    1. Kallenberg K,
    2. Bock HC,
    3. Helms G, et al

    . Untreated glioblastoma multiforme: increased myo-inositol and glutamine levels in the contralateral cerebral hemisphere at proton MRS. Radiology 2009;253:805–12 doi:10.1148/radiol.2533071654 pmid:19789222

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Cordova JS,
    2. Shu HK,
    3. Liang Z, et al

    . Whole-brain spectroscopic MRI biomarkers identify infiltrating margins in glioblastoma patients. Neuro Oncol 2016;18:1180–89 doi:10.1093/neuonc/now036 pmid:26984746

    CrossRefPubMed
26. 26.↵
    1. Ohba S,
    2. Murayama K,
    3. Abe M, et al

    . Magnetic resonance imaging and proton magnetic resonance spectroscopy for differentiating between enhanced gliomas and malignant lymphomas. World Neurosurg 2019;127:e779–87 doi:10.1016/j.wneu.2019.03.261 pmid:30951915

    CrossRefPubMed
27. 27.↵
    1. Heintz A,
    2. Chombar J,
    3. Boussida S, et al

    . P14.92 study of glutaminergic and glutamatergic metabolism in 1H-MRS monovoxel in the most aggressive part of 62 glioblastoma before and after 18 months treatment. Neuro Oncol 2019;21(Suppl 3):iii89 doi:10.1093/neuonc/noz126.327

    CrossRef
28. 28.↵
    1. Bell T,
    2. Goerzen D,
    3. Near J, et al

    . Examination of methods to optimize glutamate-glutamine separation at 3T. In: Proceedings of the International Society for Magnetic Resonance in Medicine, Virtual. August 8–14, 2020
29. 29.↵
    1. Pradhan S,
    2. Bonekamp S,
    3. Gillen JS, et al

    . Comparison of single voxel brain MRS at 3T and 7T using 32-channel head coils. Magn Reson Imaging 2015;33:1013–18 doi:10.1016/j.mri.2015.06.003 pmid:26117693

    CrossRefPubMed
30. 30.↵
    1. Lai M,
    2. Vassallo I,
    3. Lanz B, et al

    . In vivo characterization of brain metabolism by 1H MRS, 13C MRS and 18FDG PET reveals significant glucose oxidation of invasively growing glioma cells. Int J Cancer 2018;143:127–38 doi:10.1002/ijc.31299 pmid:29417580

    CrossRefPubMed
31. 31.↵
    1. Zhou R,
    2. Bagga P,
    3. Nath K, et al

    . Glutamate-weighted chemical exchange saturation transfer magnetic resonance imaging detects glutaminase inhibition in a mouse model of triple-negative breast cancer. Cancer Res 2018;78:5521–26 doi:10.1158/0008-5472.CAN-17-3988 pmid:30072394

    Abstract/FREE Full Text
32. 32.↵
    1. Harris RJ,
    2. Cloughesy TF,
    3. Liau LM, et al

    . pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. Neuro Oncol 2015;17:1514–24 doi:10.1093/neuonc/nov106 pmid:26113557

    CrossRefPubMed
33. 33.↵
    1. An L,
    2. Araneta MF,
    3. Johnson C, et al

    . Simultaneous measurement of glutamate, glutamine, GABA, and glutathione by spectral editing without subtraction. Magn Reson Med 2018;80:1776–86 doi:10.1002/mrm.27172 pmid:29575059

    CrossRefPubMed
34. 34.↵
    1. An L,
    2. Araneta MF,
    3. Victorino M, et al

    . Signal enhancement of glutamine and glutathione by single-step spectral editing. J Magn Reson 2020;316:106756 doi:10.1016/j.jmr.2020.106756 pmid:32521478

    CrossRefPubMed
35. 35.↵
    1. Zhang Y,
    2. Shen J

    . Simultaneous quantification of glutamate and glutamine by J-modulated spectroscopy at 3 Tesla. Magn Reson Med 2016;76:725–32 doi:10.1002/mrm.25922 pmid:26361892

    CrossRefPubMed
36. 36.↵
    1. Olivier C,
    2. Oliver L,
    3. Lalier L, et al

    . Drug resistance in glioblastoma: the two faces of oxidative stress. Front Mol Biosci 2020;7:620677 pmid:33585565

    PubMed
37. 37.↵
    1. Arm J,
    2. Al-Iedani O,
    3. Quadrelli S, et al

    . Reliability of neurometabolite detection with two-dimensional localized correlation spectroscopy at 3T. J Magn Reson Imaging 2018;48:1559–69 doi:10.1002/jmri.26036 pmid:29684257

    CrossRefPubMed
38. 38.↵
    1. Wang ZJ,
    2. Ohliger MA,
    3. Larson PE, et al

    . Hyperpolarized 13C MRI: state of the art and future directions. Radiology 2019;291:273–84 doi:10.1148/radiol.2019182391 pmid:30835184

    CrossRefPubMed
39. 39.↵
    1. Miloushev VZ,
    2. Granlund KL,
    3. Boltyanskiy R, et al

    . Metabolic imaging of the human brain with hyperpolarized 13C pyruvate demonstrates 13C lactate production in brain tumor patients. Cancer Res 2018;78:3755–60 doi:10.1158/0008-5472.CAN-18-0221 pmid:29769199

    CrossRefPubMed
40. 40.↵
    1. Molloy AR,
    2. Najac C,
    3. Viswanath P, et al

    . MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma. Theranostics 2020;10:8757–70 doi:10.7150/thno.47317 pmid:32754276

    CrossRefPubMed
41. 41.↵
    1. De Feyter HM,
    2. Behar KL,
    3. Corbin ZA, et al

    . Deuterium metabolic imaging (DMI) for MRI-based 3D mapping of metabolism in vivo. Sci Adv 2018;4:eaat7314 doi:10.1126/sciadv.aat7314 pmid:30140744

    FREE Full Text
42. 42.↵
    1. de Graaf RA,
    2. Hendriks AD,
    3. Klomp DW, et al

    . On the magnetic field dependence of deuterium metabolic imaging. NMR Biomed 2020;33:e4235 doi:10.1002/nbm.4235 pmid:31879985

    CrossRefPubMed
43. 43.↵
    1. Wilson M,
    2. Andronesi O,
    3. Barker PB, et al

    . Methodological consensus on clinical proton MRS of the brain: review and recommendations. Magn Reson Med 2019;82:527–50 doi:10.1002/mrm.27742 pmid:30919510

    CrossRefPubMed
44. 44.↵
    1. Sung D,
    2. Risk BB,
    3. Owusu-Ansah M, et al

    . Optimized truncation to integrate multi-channel MRS data using rank-R singular value decomposition. NMR Biomed 2020;33:e4297 doi:10.1002/nbm.4297 pmid:32249522

    CrossRefPubMed
45. 45.↵
    1. Albert NL,
    2. Weller M,
    3. Suchorska B, et al

    . Response Assessment in Neuro-Oncology Working Group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol 2016;18:1199–208 doi:10.1093/neuonc/now058 pmid:27106405

    CrossRefPubMed
46. 46.↵
    1. Miner MW,
    2. Liljenbäck H,
    3. Virta J, et al

    . (2S, 4R)-4-[(18)F] fluoroglutamine for on vivo PET imaging of glioma xenografts in mice: an evaluation of multiple pharmacokinetic models. Mol Imaging Biol 2020;22:969–78 doi:10.1007/s11307-020-01472-1 pmid:31993927

    CrossRefPubMed
47. 47.↵
    1. Xu X,
    2. Zhu H,
    3. Liu F, et al

    . Imaging brain metastasis patients with 18F-(2S,4R)-4-fluoroglutamine. Clin Nucl Med 2018;43:e392–99 doi:10.1097/RLU.0000000000002257 pmid:30179907

    CrossRefPubMed
48. 48.↵
    1. Dunphy MPS,
    2. Harding JJ,
    3. Venneti S, et al

    . In vivo PET assay of tumor glutamine flux and metabolism: in-human trial of (18)F-(2S,4R)-4-fluoroglutamine. Radiology 2018;287:667–75 doi:10.1148/radiol.2017162610 pmid:29388903

    CrossRefPubMed
49. 49.↵
    1. Schulte ML,
    2. Fu A,
    3. Zhao P, et al

    . Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models. Nat Med 2018;24:194–202 doi:10.1038/nm.4464 pmid:29334372

    CrossRefPubMed
50. 50.↵
    1. Li C,
    2. Liu H,
    3. Duan D, et al

    . Preclinical study of an 18F-labeled glutamine derivative for cancer imaging. Nucl Med Biol 2018;64-65:34–40 doi:10.1016/j.nucmedbio.2018.06.007 pmid:30041148

    CrossRefPubMed
51. 51.↵
    1. Zha Z,
    2. Ploessl K,
    3. Lieberman BP, et al

    . Alanine and glycine conjugates of (2S,4R)-4-[18F]fluoroglutamine for tumor imaging. Nucl Med Biol 2018;60:19–28 doi:10.1016/j.nucmedbio.2018.02.001 pmid:29525446

    CrossRefPubMed
52. 52.↵
    1. Cohen AS,
    2. Grudzinski J,
    3. Smith GT, et al

    . First-in-human PET imaging and estimated radiation dosimetry of L-[5-¹¹C]-glutamine in patients with metastatic colorectal cancer. J Nucl Med 2021 April 30. [Epub ahead of print] doi:10.2967/jnumed.120.261594 pmid:33931465

    CrossRefPubMed
53. 53.↵
    1. Dimitrakopoulou-Strauss A,
    2. Pan L,
    3. Sachpekidis C

    . Kinetic modeling and parametric imaging with dynamic PET for oncological applications: general considerations, current clinical applications, and future perspectives. Eur J Nucl Med Mol Imaging 2021;48:21–39 doi:10.1007/s00259-020-04843-6 pmid:32430580

    CrossRefPubMed
54. 54.↵
    1. Galldiks N,
    2. Langen K-J

    . Amino acid PET: an imaging option to identify treatment response, posttherapeutic effects, and tumor recurrence? Front Neurol 2016;7:120 doi:10.3389/fneur.2016.00120 pmid:27516754

    CrossRefPubMed
55. 55.↵
    1. Albano D,
    2. Tomasini D,
    3. Bonù M, et al

    . ¹⁸F-fluciclovine (¹⁸F-FACBC) PET/CT or PET/MRI in gliomas/glioblastomas. Ann Nucl Med 2020;34:81–86 doi:10.1007/s12149-019-01426-w pmid:31773466

    CrossRefPubMed
56. 56.↵
    1. Kampa JM,
    2. Kellner U,
    3. Marsching C, et al

    . Glioblastoma multiforme: metabolic differences to peritumoral tissue and IDH-mutated gliomas revealed by mass spectrometry imaging. Neuropathology 2020;40:546–58 doi:10.1111/neup.12671 pmid:32662157

    CrossRefPubMed
57. 57.↵
    1. Dilillo M,
    2. Ait-Belkacem R,
    3. Esteve C, et al

    . Ultra-high mass resolution MALDI imaging mass spectrometry of proteins and metabolites in a mouse model of glioblastoma. Sci Rep 2017;7:603 doi:10.1038/s41598-017-00703-w pmid:28377615

    CrossRefPubMed
58. 58.↵
    1. Fack F,
    2. Tardito S,
    3. Hochart G, et al

    . Altered metabolic landscape in IDH-mutant gliomas affects phospholipid, energy, and oxidative stress pathways. EMBO Mol Med 2017;9:1681–95 doi:10.15252/emmm.201707729 pmid:29054837

    Abstract/FREE Full Text
59. 59.↵
    1. Esteve C,
    2. Tolner EA,
    3. Shyti R, et al

    . Mass spectrometry imaging of amino neurotransmitters: a comparison of derivatization methods and application in mouse brain tissue. Metabolomics 2016;12:30 doi:10.1007/s11306-015-0926-0 pmid:26793043

    CrossRefPubMed
60. 60.↵
    1. Bernstock JD,
    2. Mooney JH,
    3. Ilyas A, et al

    . Molecular and cellular intratumoral heterogeneity in primary glioblastoma: clinical and translational implications. J Neurosurg 2019 Aug 23 [Epub ahead of print] doi:10.3171/2019.5.Jns193643 pmid:31443071

    CrossRefPubMed
61. 61.↵
    1. Besnard J,
    2. Okumoto S

    . Glutamine flux imaging using genetically encoded sensors. J Vis Exp 2014;e51657 doi:10.3791/51657 pmid:25146898

    CrossRefPubMed
62. 62.↵
    1. Gruenwald K,
    2. Holland JT,
    3. Stromberg V, et al

    . Visualization of glutamine transporter activities in living cells using genetically encoded glutamine sensors. PLoS One 2012;7:e38591 doi:10.1371/journal.pone.0038591 pmid:22723868

    CrossRefPubMed
63. 63.↵
    1. Xue M,
    2. Wei W,
    3. Su Y, et al

    . Supramolecular probes for assessing glutamine uptake enable semi-quantitative metabolic models in single cells. J Am Chem Soc 2016;138:3085–93 doi:10.1021/jacs.5b12187 pmid:26916347

    CrossRefPubMed
64. 64.↵
    1. Ghoreishi SM,
    2. Khalaj A,
    3. Sabzevari O, et al

    . Technetium-99m chelator-free radiolabeling of specific glutamine tumor imaging nanoprobe: in vitro and in vivo evaluations. Int J Nanomedicine 2018;13:4671–83 doi:10.2147/IJN.S157426 pmid:30154653

    CrossRefPubMed
65. 65.↵
    1. Jang K,
    2. Russo C,
    3. Di Ieva A

    . Radiomics in gliomas: clinical implications of computational modeling and fractal-based analysis. Neuroradiology 2020;62:771–90 doi:10.1007/s00234-020-02403-1 pmid:32249351

    CrossRefPubMed